General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
07-Jan-2020 12:51:38
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension
Announcement Reference
SG200107OTHRM9D5
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
07/01/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg

Attachments

PR_SGX_07012020_SIGNED.pdf
Total size =312K